5 Best Beaten Down Stocks to Invest in According to Analysts

4. Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Price Target Upside: 109.46%

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the best 52-week low stocks on our list.

TheFly reported on April 13 that Evercore ISI reduced its price target on VRDN to $24 from $32 while maintaining an Outperform rating ahead of the company’s first-quarter earnings update. The adjustment reflects a revised outlook incorporated into the firm’s preview of upcoming results.

In other news, it was reported earlier on April 6 that Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) declined sharply after Amgen reported positive Phase 3 results for Tepezza delivered via subcutaneous injection using an on-body device in patients with moderate to severe active thyroid eye disease. The results included achievement of both primary and secondary endpoints, increasing competitive pressure in the same treatment area where Viridian is also developing a therapy for thyroid eye disease.

Following the announcement, VRDN’s stock dropped approximately 19%, or $3.61, trading around $15.23 in morning activity. The move reflected investor concern that the new clinical data from a competing program could impact Viridian’s future commercial positioning and market expectations within the TED treatment landscape, particularly as both companies target overlapping patient populations and indications.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious rare diseases. It is primarily targeting thyroid eye disease with innovative biologic treatments designed to improve patient outcomes and reduce disease burden.